Acriptega Tablet

Acriptega Tablet contains Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate is an antiretroviral medication used in the management of HIV-1 infection.

Brand Name: Acriptega

Composition: Dolutegravir 50mg, Lamivudine 300mg, Tenofovir Disoproxil Fumarate 300mg

Mechanism of Action:

An integrase strand transfer inhibitor (INSTI) and works by blocking HIV integrase, the enzyme responsible for inserting viral DNA into the host cell's genome, thereby preventing viral replication. Lamivudine, the other component, is also an NRTI that works similarly to tenofovir by causing premature termination of the growing viral DNA chain. This is a significant gap given the product contains three active ingredients from two different mechanistic classes. The reverse transcriptase enzyme is inhibited by tenofovir, which stops viral RNA from being converted to DNA and stops the virus from multiplying inside the host cells. By lowering the blood's viral load, this dual action strengthens the immune system and lowers the risk of consequences from HIV.

Uses:

• HIV Infection

Dosage and Administration:

One tablet taken once a day, with or without food, is the usual dosage.

Side Effects:

• Fatigue
• Headache
• Nausea
• Vomiting
• Fever
• Cough
• Insomnia
• Liver Function Abnormalities
• Allergic Reactions

Contraindications/Warnings: 

This combination carries several important warnings. Tenofovir disoproxil fumarate and lamivudine (both NRTIs) carry a boxed warning for lactic acidosis and severe hepatomegaly with steatosis, which can be fatal. Tenofovir DF is also associated with nephrotoxicity, including acute kidney injury and Fanconi syndrome, and with decreases in bone mineral density — renal function should be assessed before and periodically during treatment. Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HIV and HBV who discontinue lamivudine or tenofovir-containing regimens, so hepatic function should be monitored closely for several months after stopping this medication in such patients. Dolutegravir can cause hypersensitivity reactions, occasionally with hepatic injury, and is contraindicated with dofetilide, as dolutegravir raises dofetilide plasma levels and increases the risk of serious cardiac arrhythmia. Contraindicated in patients with known hypersensitivity to any of the three components.

Safety Advise:

Kidney  

Monitor kidney function regularly, as Acriptega can cause nephrotoxicity. Kindly speak with your healthcare provider.

Liver  

Monitor liver function regularly, as Acriptega can cause liver impairment. Kindly speak with your healthcare provider.

Lungs 

No specific pulmonary toxicity has been well established for this combination. Kindly speak with your healthcare provider if you have pre-existing lung disease.

Pregnancy  

Acriptega should be used during pregnancy only if clearly needed, Kindly speak with your healthcare provider.

Breast Feeding  

Using Acriptega while nursing is most likely dangerous. Kindly speak with your healthcare provider.

Alcohol  

Acriptega should not be taken with alcohol. Kindly speak with your healthcare provider.

Storage:

Store Acriptega Tablet at a temperature between 15°C and 30°C (59°F to 86°F). Keep the tablets in the original packaging to protect them from light and moisture. Keep out of reach of children.

How to use this Medication?

Drink a glass of water along with this prescription. Take it daily at the same time as specified on the prescription label. Consume it with food. Take each dose exactly as directed on the prescription label for the best potential outcome from your therapy. Don't miss any dosages. The virus may become resistant to this and other medications if doses are skipped. Unless instructed otherwise by your care team, continue taking this therapy.
Discuss the usage of this drug in children with your care team. For certain illnesses, it can be administered to youngsters as young as 12, although there are safety precautions to take.

References:

1. Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. The Lancet. 2019 Jan 12;393(10167):143-55.

2. Scott LJ. Dolutegravir/lamivudine single-tablet regimen: a review in HIV-1 infection. Drugs. 2020 Jan;80(1):61-72.

3. Venter WD, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The lancet HIV. 2020 Oct 1;7(10):e666-76.

Reference:

1.     Tenofovir disoproxil. Limassol, Cyprus: Remedica Ltd.; 2018. [Accessed 24 Jan. 2019] (online) 

2.     Dolutegravir. Research Triangle Park, North Carolina: GlaxoSmithKline; 2013. [Accessed 24 Jan. 2019] (online)

Disclaimer:

The main goal of Apothecare Specialities Pvt Ltd is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Specialities Pvt Ltd, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Mylan Pharmaceuticals Pvt Ltd
Address: Plot No A-1/2, MIDC Industrial Area, Taloja MIDC-410208.
Country of origin: India